Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer
Ching-Yi Chen, How‐Wen Ko, Po‐Wei Hu, Cheng‐Yu Chang, Chung‐Yu Chen, Shih‐Chieh Chang, Yu-Chi Chiu, Yu‐Feng Wei
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.2147/lctt.s516527 ↗
- Volume · Issue · Pages
- Volume 16 · — · 25-37
- Publisher
- Dove Medical Press Ltd.
- Article URL
- https://doi.org/10.2147/lctt.s516527 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
01 Apr 2025
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 01 Apr 2025 | OpenAlex |
Keywords (as given): EGFR-mutant non-small cell lung cancer; small cell lung cancer transformation; EGFR tyrosine kinase inhibitors; subsequent treatment; chemotherapy; immunotherapy; EGFR exon 19 deletion; progression-free survival; overall survival; disease control rate; overall response rate; treatment sequencing; predictive biomarkers; prognostic factors; EGFR tyrosine kinase inhibitor resistance
HEC Status at Publication Not the journal's current status
HEC Status at PublicationNot conclusive
Historical status could not be conclusively determined.
- Some rows of the HEC list for this period are not yet matched to a journal, so absence cannot be proved. Pending verification.
Best available information, not a definitive status: Some rows of the HEC list for this period are not yet matched to a journal, so absence cannot be proved. Pending verification.
- Journal
- Lung Cancer: Targets and Therapy
- Publication date used
- 01 Apr 2025 (OpenAlex publication date)
- Applicable HEC period
- 2024–25 (version 1) · 01 Oct 2024 – 31 Mar 2026
- Category
- —
- Recognition status
- Pending Verification (PERIOD_HAS_UNMATCHED_ROWS)
- Source
- —
- Verification status
- Unverified
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.